Nifty
Sensex
:
:
9580.30
32424.10
90.20 (0.95%)
223.51 (0.69%)

Pharmaceuticals & Drugs - API

Rating :
63/99  (View)

BSE: 500288 | NSE: MOREPENLAB

16.00
0.25 (1.59%)
29-May-2020 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  15.80
  •  16.50
  •  15.65
  •  15.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1320253
  •  211.24
  •  23.95
  •  7.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 719.72
  • 21.78
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 699.45
  • N/A
  • 2.62

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 34.54%
  • 3.73%
  • 41.13%
  • FII
  • DII
  • Others
  • 0.74%
  • 13.39%
  • 6.47%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.75
  • 13.92
  • 8.88

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.23
  • 6.96
  • 1.93

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 68.25
  • 6.88

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.12
  • 45.83
  • 32.01

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.53
  • 4.86
  • 4.31

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 13.79
  • 16.22
  • 14.50

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Net Sales
230
212
8%
213
174
23%
203
164
24%
219
171
28%
Expenses
215
195
10%
198
157
26%
184
152
21%
197
154
28%
EBITDA
15
17
-9%
15
17
-10%
19
12
59%
22
18
22%
EBIDTM
7%
8%
7%
10%
10%
7%
10%
10%
Other Income
5
2
89%
3
0
2062%
0
0
250%
1
0
243%
Interest
1
0
26%
0
0
22%
0
0
-2%
1
1
15%
Depreciation
9
10
-13%
8
10
-16%
12
9
26%
11
10
7%
PBT
11
9
20%
9
7
36%
8
3
190%
11
7
54%
Tax
0
0
-92%
5
0
-
0
0
-89%
0
0
-
PAT
11
9
21%
4
7
-41%
8
2
211%
10
7
50%
PATM
5%
4%
2%
4%
4%
2%
5%
4%
EPS
0.24
0.20
20%
0.09
0.16
-44%
0.17
0.05
240%
0.23
0.16
44%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
865
769
607
595
485
401
367
326
289
228
212
Net Sales Growth
20%
27%
2%
23%
21%
9%
13%
13%
27%
8%
 
Cost Of Goods Sold
571
479
361
358
293
239
209
194
178
143
127
Gross Profit
294
289
245
237
192
162
158
132
111
86
85
GP Margin
34%
38%
40%
40%
40%
40%
43%
41%
38%
38%
40%
Total Expenditure
794
701
542
534
424
352
318
295
270
223
200
Power & Fuel Cost
-
13
11
10
8
7
8
9
10
8
6
% Of Sales
-
2%
2%
2%
2%
2%
2%
3%
3%
3%
3%
Employee Cost
-
95
77
70
58
49
45
39
36
31
23
% Of Sales
-
12%
13%
12%
12%
12%
12%
12%
12%
13%
11%
Manufacturing Exp.
-
31
16
22
13
13
12
11
10
11
9
% Of Sales
-
4%
3%
4%
3%
3%
3%
3%
4%
5%
4%
General & Admin Exp.
-
36
29
18
18
16
17
14
14
13
13
% Of Sales
-
5%
5%
3%
4%
4%
5%
4%
5%
6%
6%
Selling & Distn. Exp.
-
33
30
26
23
21
20
20
16
11
18
% Of Sales
-
4%
5%
4%
5%
5%
5%
6%
5%
5%
9%
Miscellaneous Exp.
-
13
18
30
9
8
7
8
6
6
18
% Of Sales
-
2%
3%
5%
2%
2%
2%
2%
2%
3%
1%
EBITDA
71
68
65
61
62
48
49
31
19
6
12
EBITDA Margin
8%
9%
11%
10%
13%
12%
13%
10%
7%
3%
5%
Other Income
9
4
4
4
1
1
1
3
1
1
0
Interest
2
2
4
8
10
9
10
12
8
6
4
Depreciation
39
40
34
34
35
39
46
46
48
48
48
PBT
38
29
30
24
17
2
-6
-24
-36
-48
-40
Tax
5
0
0
0
0
0
0
0
0
-1
0
Tax Rate
14%
1%
0%
0%
-1%
6%
0%
0%
0%
1%
0%
PAT
33
29
30
24
13
2
-3
-21
-24
-47
-6
PAT before Minority Interest
33
29
30
24
13
2
-3
-21
-24
-47
-6
Minority Interest
0
0
0
0
0
0
0
0
0
0
0
PAT Margin
4%
4%
5%
4%
3%
1%
-1%
-6%
-8%
-21%
-3%
PAT Growth
31%
-2%
25%
85%
498%
177%
86%
13%
50%
-654%
 
EPS
0.73
0.64
0.66
0.53
0.28
0.05
-0.06
-0.46
-0.53
-1.04
-0.14

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
253
226
196
300
287
297
300
320
344
391
Share Capital
90
90
90
210
210
210
210
210
210
210
Total Reserves
163
136
106
91
78
88
90
111
134
181
Non-Current Liabilities
23
20
18
57
74
85
104
122
135
140
Secured Loans
2
3
1
43
62
75
95
99
114
128
Unsecured Loans
0
0
0
0
0
0
0
15
14
11
Long Term Provisions
19
14
14
11
9
8
7
6
4
0
Current Liabilities
339
340
325
167
128
108
103
105
103
85
Trade Payables
168
175
125
115
85
69
57
65
60
82
Other Current Liabilities
161
164
199
47
40
38
45
39
41
0
Short Term Borrowings
9
0
0
0
2
1
0
0
0
0
Short Term Provisions
1
1
1
4
1
1
1
1
2
3
Total Liabilities
615
586
538
524
489
490
506
547
581
616
Net Block
236
264
272
297
322
368
409
452
496
540
Gross Block
888
998
1,027
1,018
1,009
1,005
1,000
997
998
996
Accumulated Depreciation
652
733
755
722
687
637
591
546
502
455
Non Current Assets
316
342
346
367
374
393
415
457
501
544
Capital Work in Progress
0
0
0
0
0
0
0
0
0
0
Non Current Investment
0
0
0
0
0
0
4
4
4
4
Long Term Loans & Adv.
79
78
74
70
52
25
2
2
1
0
Other Non Current Assets
0
0
1
0
0
0
0
0
0
0
Current Assets
299
243
192
157
115
96
91
90
80
70
Current Investments
0
0
0
0
0
0
0
0
0
0
Inventories
94
77
65
42
37
33
37
39
35
32
Sundry Debtors
134
122
93
88
56
43
39
35
30
24
Cash & Bank
32
6
8
4
9
9
6
5
3
1
Other Current Assets
39
6
5
6
12
11
9
11
13
13
Short Term Loans & Adv.
31
33
22
17
9
8
6
10
10
11
Net Current Assets
-40
-97
-133
-9
-13
-12
-12
-15
-23
-15
Total Assets
615
586
538
524
489
490
506
547
581
616

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
17
63
41
50
51
34
34
27
11
7
PBT
29
30
23
17
2
-6
-24
-36
-48
-40
Adjustment
40
39
41
46
47
56
57
56
54
52
Changes in Working Capital
-52
-5
-24
-8
1
-20
-3
-5
4
-4
Cash after chg. in Working capital
18
63
41
54
51
31
31
15
10
7
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
0
0
0
0
0
0
0
0
1
0
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
-4
0
0
0
0
0
0
Cash From Investing Activity
-13
-27
-14
-27
-32
-1
-3
-3
-4
-4
Net Fixed Assets
113
32
-8
-7
-5
-4
-3
1
-2
-4
Net Investments
0
0
0
0
0
4
0
0
0
0
Others
-126
-59
-6
-21
-27
-1
0
-4
-2
0
Cash from Financing Activity
0
-38
-24
-27
-19
-29
-30
-22
-6
-6
Net Cash Inflow / Outflow
4
-1
3
-4
0
4
1
2
1
-3
Opening Cash & Equivalents
6
7
4
9
9
6
5
3
1
5
Closing Cash & Equivalent
10
6
7
4
9
9
6
5
3
1

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
6
5
4
4
4
4
4
4
5
6
ROA
5%
5%
4%
3%
0%
-1%
-4%
-4%
-8%
-1%
ROE
12%
14%
13%
7%
1%
-2%
-11%
-11%
-19%
-3%
ROCE
12%
14%
10%
6%
3%
2%
-2%
-3%
-8%
0%
Fixed Asset Turnover
0.82
0.60
0.58
0.49
0.41
0.37
0.33
0.29
0.23
0.21
Receivable days
61
65
55
53
44
40
41
40
42
39
Inventory Days
41
43
33
29
31
35
42
46
52
46
Payable days
89
103
83
84
76
68
69
76
102
125
Cash Conversion Cycle
12
4
5
-1
0
7
13
10
-7
-39
Total Debt/Equity
0.05
0.06
0.25
0.22
0.28
0.30
0.37
0.38
0.39
0.36
Interest Cover
15
8
4
2
1
1
-1
-2
-7
-1

News Update


  • Morepen Laboratories gets ISO-13485 certification for Baddi medical devices manufacturing facility
    30th Apr 2020, 11:04 AM

    The certification has been awarded for the manufacturing, distribution and after sales service of all point-of-care diagnostic medical devices and their accessories

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.